GSK boss does not see mass-produced coronavirus vaccine before mid-2021 [Reuters (UK)]
GlaxoSmithKline PLC (GSK)
US:NYSE Investor Relations:
gsk.com/en-gb/investors
Company Research
Source: Reuters
GSK boss sees no coronavirus vaccine mass-produced before mid-2021 - Reuters 1 Min Read (Reuters) - The chief executive of the world’s largest vaccine maker, GlaxoSmithKline ( GSK.L ), said the global push to develop an immunisation against the coronavirus would not lead to widely available products before the second half of next year. “If things go right ... to get to scale of manufacturing in the hundreds of millions (of doses) is going to be in the second half of next year,” CEO Emma Walmsley told a media briefing after the release of first-quarter results. Reporting by Ludwig Burger; Editing by Edmund Blair All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. © 2020 Reuters. All Rights Reserved.
Show less
Read more
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GSK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GSK alerts
High impacting GlaxoSmithKline PLC news events
Weekly update
A roundup of the hottest topics
GSK
News
- GSK (NYSE:GSK) had its "buy (b)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- GSK (NYSE:GSK) was upgraded by analysts at Bank of America Corporation from an "underperform" rating to a "neutral" rating.MarketBeat
- GSK (NYSE:GSK) had its "buy (b)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Deutsche Bank Maintains a Hold Rating on GSK plc (GSK) [Yahoo! Finance]Yahoo! Finance
- GSK (NYSE:GSK) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "hold (c+)" rating to a "buy (b-)" rating.MarketBeat
GSK
Sec Filings
- 12/5/25 - Form 6-K
- 12/4/25 - Form 6-K
- 12/3/25 - Form 6-K
- GSK's page on the SEC website